Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management

References

• National Comprehensive Cancer Network. NCCN guidelines. Pediatric acute lymphoblastic leukemia. Version 1.2022; 2021. https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf
   Google Scholar
• Burke MJ. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Future Oncol. 2014;10(16):2615–2627.
   PubMed Web of Science ®Google Scholar
• Ueno T, Ohtawa K, Mitsui K, et al. Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia. 1997;11(11):1858–1861.
   PubMed Web of Science ®Google Scholar
• Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56(8):2273–2280.
   PubMed Web of Science ®Google Scholar
• Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(4):748–757.
   PubMed Web of Science ®Google Scholar
• Heo Y-A, Syed YY, Keam SJ. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019;79(7):767–777.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group study AALL07P4. J Clin Oncol. 2014;32(34):3874–3882.
   PubMed Web of Science ®Google Scholar
• Peterson RE, Ciegler A. L-asparaginase production by Erwinia aroideae. Appl Microbiol. 1969;18(1):64–67.
   PubMedGoogle Scholar
• Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer. 1972;30(2):376–381.
   PubMed Web of Science ®Google Scholar
• Baruchel A, Brown P, Rizzari C, et al. Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open. 2020;5(5):e000977.
   PubMed Web of Science ®Google Scholar
• RYLAZE^® (asparaginase erwinia chrysanthemi (recombinant)-rywn) [package insert]. Leinster, Ireland: Jazz Pharmaceuticals Ireland Limited; 2022.
   Google Scholar
• US Food and Drug Administration. FDA drug shortages. Asparaginase Erwinia chrysanthemi (Erwinaze). 2022. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Asparaginase%20Erwinia%20Chrysanthemi%20(Erwinaze)&st=c
   Google Scholar
• Verma A, Chen K, Bender C, et al. PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability. Pediatr Hematol Oncol. 2019;36(5):277–286.
   PubMed Web of Science ®Google Scholar
• Lin T, Hernandez-Illas M, Rey A, et al. A randomized phase I study to evaluate the safety, tolerability, and pharmacokinetics of recombinant Erwinia asparaginase (JZP-458) in healthy adult volunteers. Clin Transl Sci. 2021;14(3):870–879.
   PubMed Web of Science ®Google Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335–342.
   PubMed Web of Science ®Google Scholar
• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161–7167.
   PubMed Web of Science ®Google Scholar
• LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL consortium protocol 87-01. J Clin Oncol. 2002;20(1):237–246.
   PubMed Web of Science ®Google Scholar
• Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677–1690.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Blonquist TM, Stevenson KE, et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood. 2001;97(5):1211–1218.
   PubMed Web of Science ®Google Scholar
• Gottschalk Højfeldt S, Grell K, Abrahamsson J, et al. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood. 2021;137(17):2373–2382.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2020;38(17):1897–1905.
   PubMed Web of Science ®Google Scholar
• Maese LD, Loh ML, Choi MR, et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2022. doi:10.1182/blood.2022016923. Online ahead of print.
   Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, Children’s Cancer Group Study CCG-1961, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217–226.
   PubMed Web of Science ®Google Scholar
• Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26(11):2303–2309.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institute ALL consortium protocol 00-01. J Clin Oncol. 2013;31(9):1202–1210.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2026–2033.
   PubMed Web of Science ®Google Scholar
• Liu Y, Smith CA, Panetta JC, et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051–2061.
   PubMed Web of Science ®Google Scholar
• Geyer MB, Ritchie EK, Rao AV, et al. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021;106(8):2086–2094.
   PubMed Web of Science ®Google Scholar
• Klug Albertsen B, Schmiegelow K, Schrøder H, et al. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study. Cancer Chemother Pharmacol. 2002;50(2):117–120.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Kirov II, Dreyer ZE, et al. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63(2):228–233.
   PubMed Web of Science ®Google Scholar
• Kloos R, van der Sluis IM, Mastrobattista E, et al. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker. Br J Haematol. 2020;189(3):442–451.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Młynarski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48(5):931–936.
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103–111.
   PubMed Web of Science ®Google Scholar
• Rau RE, Dreyer Z, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018;65(3):e26873.
   Web of Science ®Google Scholar
• van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279–285.
   PubMed Web of Science ®Google Scholar
• Mondelaers V, Ferster A, Uyttebroeck A, et al. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. Br J Haematol. 2020;190(1):105–114.
   PubMed Web of Science ®Google Scholar
• Steiner M, Attarbaschi A, Kastner U, et al. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. Pediatr Blood Cancer. 2007;49(5):640–642.
   PubMed Web of Science ®Google Scholar
• Heitink-Pollé KM, Prinsen BH, de Koning TJ, et al. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 2013;7:103–108.
   PubMedGoogle Scholar
• Woods D, Winchester K, Towerman A, et al. From the Children's Oncology Group: evidence-based recommendations for PEG-asparaginase nurse monitoring, hypersensitivity reaction management, and patient/family education. J Pediatr Oncol Nurs. 2017;34(6):387–396.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, van der Sluis IM. Ammonia levels should not be used as a surrogate marker of levels of asparaginase activity in acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2016;63(3):564–565.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Miyake K, Ogawa C, et al. The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia. Int J Hematol. 2009;90(3):347–352.
   PubMed Web of Science ®Google Scholar
• Czogała M, Balwierz W, Sztefko K, et al. Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia. Biomed Res Int. 2014;2014:945860.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017;58(3):540–551.
   PubMed Web of Science ®Google Scholar
• National Institute for Heath and Care Excellence (NICE). Anaphylaxis: assessment and referral after emergency treatment. https://www.nice.org.uk/guidance/cg134.
   Google Scholar
• Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis—a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341–384.
   PubMed Web of Science ®Google Scholar
• Kloos RQH, Pieters R, Jumelet FMV, et al. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J Clin Oncol. 2020;38(7):715–724.
   PubMed Web of Science ®Google Scholar
• Kearney SL, Dahlberg SE, Levy DE, et al. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009;53(2):162–167.
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–615.
   PubMed Web of Science ®Google Scholar
• Samarasinghe S, Dhir S, Slack J, et al. Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2013;162(5):710–713.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang W, Devidas M, et al. Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. J Clin Oncol. 2016;34(18):2133–2140.
   PubMed Web of Science ®Google Scholar
• Rank CU, Wolthers BO, Grell K, et al. Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1–45 years of age. J Clin Oncol. 2020;38(2):145–154.
   PubMed Web of Science ®Google Scholar
• Erwinase^® (crisantaspase) [summary of product characteristics]. Lyon, France: Jazz Pharmaceuticals, Inc; 2016.
   Google Scholar
• Lynggaard LS, Rank CU, Hansen SN, et al. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study. Blood Adv. 2022;6(1):138–147.
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896–904.
   PubMed Web of Science ®Google Scholar
• Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003—re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010;149(3):410–413.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–459.
   PubMed Web of Science ®Google Scholar
• Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018;131(22):2475–2484.
   PubMed Web of Science ®Google Scholar
• Orvain C, Balsat M, Tavernier E, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020;136(3):328–338.
   PubMed Web of Science ®Google Scholar
• Asparlas (calaspargase pegol-mknl) [prescribing information]. Boston, MA: Servier Pharmaceuticals LLC; 2021.
   Google Scholar
• Zwicker JI, Wang T-F, DeAngelo DJ, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH. J Thromb Haemost. 2020;18(2):278–284.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–2253.
   PubMed Web of Science ®Google Scholar
• Elspar (asparaginase) [prescribing information]. Deerfield (IL): Lundbeck; 2013.
   Google Scholar
• Oncaspar (pegaspargase) [prescribing information]. Boston (MA): Servier Pharmaceuticals LLC; 2021.
   Google Scholar
• Erwinase (asparaginase Erwinia chrysanthemi) [prescribing information]. Palo Alto (CA): Jazz Pharmaceuticals, Inc.; 2019.
   Google Scholar
• Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer—Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734–2739.
   PubMed Web of Science ®Google Scholar
• Hempel G, Müller HJ, Lanvers-Kaminsky C, et al. A population pharmacokinetic model for pegylated-asparaginase in children. Br J Haematol. 2010;148(1):119–125.
   PubMed Web of Science ®Google Scholar
• Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;86(6):651–658.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11(9):1780–1786.
   PubMed Web of Science ®Google Scholar
• Kloos RQH, Mathôt R, Pieters R, et al. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. Haematologica. 2021;106(5):1254–1261.
   PubMed Web of Science ®Google Scholar
• Hasan H, Shaikh OM, Rassekh SR, et al. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic review. Pediatr Blood Cancer. 2017;64(1):81–88.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on Children's Oncology Group (COG) clinical trials. Leuk Lymphoma. 2018;59(7):1624–1633.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines. Acute lymphoblastic leukemia. Version 4.2021; January 2022. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
   Google Scholar
• Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797–1806.
   PubMed Web of Science ®Google Scholar
• Schore RJ, Devidas M, Bleyer A, et al. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. Leuk Lymphoma. 2019;60(7):1740–1748.
   PubMed Web of Science ®Google Scholar
• Vieira Pinheiro JP, Ahlke E, Nowak-Göttl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol. 1999;104(2):313–320.
   PubMed Web of Science ®Google Scholar
• Bade NA, Lu C, Patzke CL, et al. Optimizing pegylated asparaginase use: an institutional guideline for dosing, monitoring, and management. J Oncol Pharm Pract. 2020;26(1):74–92.
   PubMed Web of Science ®Google Scholar
• Marini BL, Brown J, Benitez L, et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019;60(12):2854–2868.
   PubMed Web of Science ®Google Scholar
• Chang A, Kim M, Seyer M, et al. Allergic reactions associated with pegaspargase in adults. Leuk Lymphoma. 2016;57(7):1665–1668.
   PubMed Web of Science ®Google Scholar
• Cooper SL, Young DJ, Bowen CJ, et al. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797.
   PubMed Web of Science ®Google Scholar
• Swanson HD, Panetta JC, Barker PJ, et al. Predicting success of desensitization after pegaspargase allergy. Blood. 2020;135(1):71–75.
   PubMed Web of Science ®Google Scholar
• August KJ, Farooki S, Fulbright JM, et al. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer. 2020;67(1):e28021.
   PubMed Web of Science ®Google Scholar
• Boissel N, Sender LS. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase. J Adolesc Young Adult Oncol. 2015;4(3):118–128.
   PubMed Web of Science ®Google Scholar
• Advani AS, Larsen E, Laumann K, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021;5(2):504–512.
   PubMed Web of Science ®Google Scholar
• Henriksen LT, Harila-Saari A, Ruud E, Nordic Society of Paediatric Haematology and Oncology (NOPHO) group, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;62(3):427–433.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375–380.
   PubMed Web of Science ®Google Scholar
• Denton CC, Rawlins YA, Oberley MJ, et al. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018;65(3):e26891.
   Web of Science ®Google Scholar
• Derman BA, Streck M, Wynne J, et al. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(3):614–622.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020;135(13):987–995.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 9511. Blood. 2007;109(10):4164–4167.
   PubMed Web of Science ®Google Scholar
• Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015;125(24):3702–3710.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526–534.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Zembillas AS. Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: a call for action. Pediatr Blood Cancer. 2021;68(3):e28743.
   PubMed Web of Science ®Google Scholar
• Burke PW, Hoelzer D, Park JH, et al. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion. ESMO Open. 2020;5(5):e000858.
   PubMed Web of Science ®Google Scholar
• Schulte RR, Madiwale MV, Flower A, et al. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. Leuk Lymphoma. 2018;59(10):2360–2368.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99(6):1986–1994.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Tissing WJE, et al. Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase. Haematologica. 2014;99(7):e102–e104.
   PubMed Web of Science ®Google Scholar